Leap Therapeutics (LPTX)
(Delayed Data from NSDQ)
$2.56 USD
+0.09 (3.64%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Leap Therapeutics, Inc. (LPTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.70 | $16.00 | $5.50 | 333.20% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Leap Therapeutics, Inc. comes to $10.70. The forecasts range from a low of $5.50 to a high of $16.00. The average price target represents an increase of 333.2% from the last closing price of $2.47.
Analyst Price Targets (5 )
Broker Rating
Leap Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.25 a month ago based on four recommendations.
Of the five recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 80% and 20% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.20 | 1.20 | 1.25 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
8/12/2024 | Raymond James | Timur Ivannikov | Moderate Buy | Moderate Buy |
6/28/2024 | Rodman & RenshawCo. | Tony Butler | Not Available | Strong Buy |
5/13/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
3/19/2024 | Robert W. Baird & Co. | Joel L Beatty | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.20 |
ABR (Last week) | 1.20 |
# of Recs in ABR | 5 |
Average Target Price | $10.70 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | -0.46 |
LPTX FAQs
Leap Therapeutics, Inc. (LPTX) currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 5 brokerage firms.
The average price target for Leap Therapeutics, Inc. (LPTX) is $10.70. The current on short-term price targets is based on 3 reports.
The forecasts for Leap Therapeutics, Inc. (LPTX) range from a low of $5.5 to a high of $16. The average price target represents a increase of $317.97 from the last closing price of $2.56.
The current UPSIDE for Leap Therapeutics, Inc. (LPTX) is 317.97%
Based on short-term price targets offered by five analysts, the average price target for Leap Therapeutics, Inc. comes to $10.70. The forecasts range from a low of $5.50 to a high of $16.00. The average price target represents an increase of 333.2% from the last closing price of $2.47.